Shuttle Pharmaceuticals Inc (SHPH): Boom .62

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	184
Posts	21897
Boards Moderated	0
Alias Born	08/14/2011

tw0122

Re: None

Wednesday, 12/27/2023 4:07:18 PM

Wednesday, December 27, 2023 4:07:18 PM

Boom .62

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SHPH News

Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 01:00:22 PM
Shuttle Pharma Provides First Quarter 2024 Corporate Update • GlobeNewswire Inc. • 05/14/2024 01:00:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 09:01:59 PM
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/23/2024 08:15:00 PM
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update • PR Newswire (US) • 03/22/2024 01:00:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 11:18:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 02:00:29 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:00:16 PM
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering • PR Newswire (US) • 02/13/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:25:13 PM
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 • PR Newswire (US) • 01/23/2024 09:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:05:10 PM
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma • PR Newswire (US) • 01/08/2024 02:00:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:10:30 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:51:28 AM
Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:10:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 02:00:12 PM
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma • PR Newswire (US) • 12/11/2023 02:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 02:00:25 PM
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update • PR Newswire (US) • 11/14/2023 02:00:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:21:44 PM
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement • PR Newswire (US) • 10/31/2023 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 09:14:44 PM
Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 10/20/2023 08:15:34 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 08:10:11 PM

More SHPH News

InvestorsHub NewsWire

"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM

North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM

VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM

ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover